Compare Abeona Therapeutics Inc (ABEO) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Direxion Daily FTSE China Bull 3x Shares trades at $25.3. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| ABEO | YINN | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $56.62 |
52-Week Low | $4.17 | $21.45 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $23.30, up 5.53% with a bearish technical signal from moving averages. The ETF faces structural risks from its leveraged exposure to Chinese equities, though recent sentiment shows some improvement as China's tech sector benefits from AI investments and export growth. Key support sits at $22-23 with resistance at $24.
Outlook remains cautious due to YINN's leveraged structure and China's regulatory environment. While AI-driven growth and index rebalancing may provide short-term catalysts, long-term risks include geopolitical tensions and valuation concerns. Investors should weigh the ETF's daily reset mechanism against China's economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
